The surprising results when drug development and altruism collide

By Megan Scudellari The Profits of Nonprofit The surprising results when drug development and altruism collide Victoria Hale, founder of the Institute of OneWorld Health, the first nonprofit pharmaceutical company in the US POPTECH In the beginning, they called her a fool. When pharmaceutical chemist Victoria Hale told friends and colleagues that she wanted to start a nonprofit pharma company, they laughed at her, said it was career suicide, that it could

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

The state’s industry draws inspiration from medicine as well as agriculture.

Collaborators say a new formula is needed to turn neglected molecules into treatments

SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h

There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.

George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.

The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.